Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
01 August 2022 - 5:00PM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announced today that the Australian
Patent Office (IP Australia) granted a notice of allowance to
Biofrontera Bioscience GmbH for the patent "Photodynamic therapy
comprising two light exposures at different wavelengths" (AU
2018/437303B2).
The patent protects a number of innovations
related to new illumination protocols for the treatment of skin
diseases with photodynamic therapy (PDT). It covers treatment
protocols that are expected to combine the lower pain of daylight
PDT with the higher cure rates and lower recurrence rates of
conventional therapy. The patent also claims this illumination
approach is linked to the performance of PDT with a drug containing
a photosensitizer or its precursor. In this respect, the use of the
illumination combinations protected in this patent also protects
Biofrontera’s drug, Ameluz®.
“The news of the patent allowance in Australia
for our licensor Biofrontera Bioscience GmbH demonstrates the
potential for continued innovation and further improvements in PDT
therapy that our products are on the forefront of. By offering
conventional therapy’s efficacy at a lower pain intensity and
reduced patient presence in the doctor’s office, Biofrontera’s
products and PDT in general have a strong competitive advantage.
The patent strengthens the differentiated profile of the
BF-RhodoLED® and Ameluz combination, Ameluz-PDT, and provides a
potential roadmap for similar patent extensions and further
protection of Ameluz-PDT in other geographies, including the United
States,” stated Hermann Luebbert, Executive Chairman of Biofrontera
Inc.
The treatment method uses a photosensitizer in
combination with two light exposures of different wavelengths and
exposure durations. The application of a photosensitizer is
followed first by a longer exposure to a broadband light (e.g.,
sunlight or light from an appropriate artificial light source) or
blue light, followed by a subsequent, much shorter exposure to
narrowband red light (e.g., light from Biofrontera's RhodoLED®
lamps).
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024